Compare Stocks: LEGN, HALO, BBIO, and SMMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$70.95 +2.3%	$70.94	$60.22 ▼ $93.42	$13.86B	0.97	2.87 million shs	1.13 million shs
HALO Halozyme Therapeutics	$129.26 +0.6%	$112.23	$61.22 ▼ $129.69	$14.66B	0.88	1.94 million shs	425,333 shs
LEGN Legend Biotech	$22.63 +5.0%	$19.54	$16.24 ▼ $37.50	$4.39B	0.57	2.39 million shs	1.29 million shs
SMMT Summit Therapeutics	$15.35 +0.2%	$15.86	$12.07 ▼ $29.23	$12.24B	-1.51	4.62 million shs	1.28 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+1.79%	+2.69%	+5.80%	-16.96%	+9.14%
HALO Halozyme Therapeutics	+0.38%	+3.32%	+12.82%	+54.30%	+95.14%
LEGN Legend Biotech	+5.74%	+13.41%	+12.82%	+14.10%	-32.88%
SMMT Summit Therapeutics	+5.72%	-4.72%	-1.79%	+19.77%	-21.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$70.95 +2.3%	$70.94	$60.22 ▼ $93.42	$13.86B	0.97	2.87 million shs	1.13 million shs
HALO Halozyme Therapeutics	$129.26 +0.6%	$112.23	$61.22 ▼ $129.69	$14.66B	0.88	1.94 million shs	425,333 shs
LEGN Legend Biotech	$22.63 +5.0%	$19.54	$16.24 ▼ $37.50	$4.39B	0.57	2.39 million shs	1.29 million shs
SMMT Summit Therapeutics	$15.35 +0.2%	$15.86	$12.07 ▼ $29.23	$12.24B	-1.51	4.62 million shs	1.28 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+1.79%	+2.69%	+5.80%	-16.96%	+9.14%
HALO Halozyme Therapeutics	+0.38%	+3.32%	+12.82%	+54.30%	+95.14%
LEGN Legend Biotech	+5.74%	+13.41%	+12.82%	+14.10%	-32.88%
SMMT Summit Therapeutics	+5.72%	-4.72%	-1.79%	+19.77%	-21.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.87	Moderate Buy	$104.40	50.50% Upside
HALO Halozyme Therapeutics	2.77	Moderate Buy	$99.55	-22.53% Downside
LEGN Legend Biotech	2.53	Moderate Buy	$54.69	153.67% Upside
SMMT Summit Therapeutics	2.58	Moderate Buy	$28.61	86.61% Upside

Current Analyst Ratings Breakdown

Latest LEGN, HALO, BBIO, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/26/2026	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/21/2026	BBIO BridgeBio Pharma	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$97.00 ➝ $87.00
10/19/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/19/2026	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$115.00 ➝ $120.00
10/19/2026	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$94.00 ➝ $91.00
10/16/2026	HALO Halozyme Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$130.00
10/15/2026	SMMT Summit Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$82.00 ➝ $92.00
10/14/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	$1.27B	3.29	N/A	N/A	N/A	∞
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	N/A	-$3.57	N/A	N/A	N/A	N/A	N/A	N/A	10/29/2026 (Estimated)
HALO Halozyme Therapeutics	N/A	$3.35	N/A	13.13	N/A	N/A	N/A	N/A	11/5/2026 (Estimated)
LEGN Legend Biotech	N/A	-$0.25	N/A	18.59	N/A	N/A	N/A	N/A	11/11/2026 (Estimated)
SMMT Summit Therapeutics	N/A	-$1.12	N/A	N/A	N/A	N/A	N/A	N/A	11/2/2026 (Estimated)

Latest LEGN, HALO, BBIO, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	LEGN Legend Biotech	$0.01	N/A	N/A	N/A	$361.46 million	N/A
11/11/2026	Q3 2026	SMMT Summit Therapeutics	-$0.2806	N/A	N/A	N/A	$0.07 million	N/A
11/5/2026	Q3 2026	HALO Halozyme Therapeutics	$2.30	N/A	N/A	N/A	$490.85 million	N/A
11/2/2026	Q3 2026	SMMT Summit Therapeutics	-$0.2806	N/A	N/A	N/A	$0.07 million	N/A
10/29/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.5423	N/A	N/A	N/A	$293.47 million	N/A
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
HALO Halozyme Therapeutics	97.79%
LEGN Legend Biotech	70.89%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
HALO Halozyme Therapeutics	2.50%
LEGN Legend Biotech	0.02%
SMMT Summit Therapeutics	81.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	839	N/A	167.67 million	Optionable
HALO Halozyme Therapeutics	423	N/A	110.66 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
SMMT Summit Therapeutics	265	799.73 million	145.55 million	Optionable

LEGN, HALO, BBIO, and SMMT Headlines

Recent News About These Companies

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts (SMMT)

...

October 26 at 8:35 AM | marketbeat.com

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

October 25 at 4:00 PM | gurufocus.com

October 25 at 11:52 AM | businesswire.com

Summit Therapeutics and Lunit partner on AI pathology for cancer research

October 24, 2026 | streetinsider.com

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

October 23, 2026 | prnewswire.com

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

October 23, 2026 | businesswire.com

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

October 22, 2026 | zacks.com

Summit Therapeutics PLC (NASDAQ:SMMT) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 22, 2026 | americanbankingnews.com

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary ...

October 21, 2026 | manilatimes.netM

Summit Therapeutics and ECOG-ACRIN to trial ivonescimab in bile duct cancer

October 21, 2026 | streetinsider.com

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

October 21, 2026 | zacks.com

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

October 21, 2026 | prnewswire.com

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

October 21, 2026 | businesswire.com

Summit Therapeutics Stock Rises 7% Over Initiation Of Global Phase II Study Of Ivonescimab

October 19, 2026 | rttnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Up 6.1% - Still a Buy?

October 19, 2026 | marketbeat.com

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

October 19, 2026 | finance.yahoo.com

Summit Therapeutics PLC (NASDAQ:SMMT) Stock Has Average Price Target of $28.61

October 17, 2026 | marketbeat.com

Summit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)

October 13, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Down 5.8% - Here's What Happened

October 13, 2026 | marketbeat.com

Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on Monday

October 12, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Stock Jumps 3.6% - What's Next?

October 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LEGN, HALO, BBIO, and SMMT Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$70.95 +1.58 (+2.28%)

As of 01:34 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Halozyme Therapeutics NASDAQ:HALO

$129.26 +0.76 (+0.59%)

As of 01:34 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Legend Biotech NASDAQ:LEGN

$22.63 +1.07 (+4.96%)

As of 01:33 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Summit Therapeutics NASDAQ:SMMT

$15.35 +0.02 (+0.16%)

As of 01:34 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEGN, HALO, BBIO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEGN, HALO, BBIO, and SMMT Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEGN, HALO, BBIO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LEGN, HALO, BBIO, and SMMT Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Legend Biotech NASDAQ:LEGN

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEGN, HALO, BBIO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEGN, HALO, BBIO, and SMMT Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEGN, HALO, BBIO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LEGN, HALO, BBIO, and SMMT Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Legend Biotech NASDAQ:LEGN

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools